Voyager Therapeutics, Inc.
VYGR
$3.47
-$0.06-1.70%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -161.15% | 65.08% | 54.34% | -109.13% | 338.70% |
| Total Depreciation and Amortization | -24.27% | 19.79% | 28.18% | 11.26% | 60.07% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 75.43% | 43.49% | 66.95% | -34.20% | -52.89% |
| Change in Net Operating Assets | 120.16% | -868.03% | -256.26% | 1,723.58% | -1,158.79% |
| Cash from Operations | 38.85% | -32.86% | -3,682.04% | -52.44% | -94.05% |
| Capital Expenditure | 79.47% | 67.01% | 20.08% | -320.63% | 19.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -198.04% | 141.02% | -49.13% | -726.16% | 83.92% |
| Cash from Investing | -201.38% | 140.65% | -45.74% | -762.93% | 90.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 24.78% | -95.77% | -63.11% | 260.49% | 66.67% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 24.78% | -95.77% | -63.11% | 260.49% | 66.67% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,264.96% | 120.33% | -179.55% | -55.39% | 68.32% |